One cohort of mice received the VEGFR2 inhibitor DC101 at 1 hour preceding SDRT, a time optimized by our group for derepressing ASMase to sensitize B16F1 melanoma and MCA/129 fibrosarcoma xenografts to a single high-dose radiation exposure (22, 23). The gene discussed is SMPD1; the disease is melanoma.